Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines

Brain and Development

Volumn 34, Issue 3, 2012, Pages 213-222

  Harahap, Indra Sari Kusuma ^a,b   Saito, Toshio ^c   San, Lai Poh ^d   Sasaki, Naoko ^a   Gunadi, ^a   Nurputra, Dian Kesuma Pramudya ^a   Yusoff, Surini ^a   Yamamoto, Tomoto ^a   Morikawa, Satoru ^a   Nishimura, Noriyuki ^a   Lee, Myeong Jin ^a   Takeshima, Yasuhiro ^a   Matsuo, Masafumi ^a   Nishio, Hisahide ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c TONEYAMA NATIONAL HOSPITAL   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; SPLICING FACTOR 2; SURVIVAL MOTOR NEURON PROTEIN 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EXON; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; SPINAL MUSCULAR ATROPHY; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CELL LINE; FIBROBLASTS; GENE EXPRESSION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; INFANT; MUSCULAR ATROPHY, SPINAL; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; SURVIVAL OF MOTOR NEURON 2 PROTEIN; TRANSCRIPTION, GENETIC; VALPROIC ACID;

EID: 84856962413     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2011.04.010     Document Type: Article

References (58)

1. Feldkötter M., Schwarzer V., Wirth R., Wienker T.F., Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002, 70:358-368.
2. Zerres K., Davies K.E. 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The Netherlands. Neuromuscul Disord 1999, 9:272-278.
3. Brzustowicz L.M., Lehner T., Castilla L.H., Penchaszadeh G.K., Wilhelmsen K.C., Daniels R., et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990, 344:540-541.
4. Gilliam T.C., Brzustowicz L.M., Castilla L.H., Lehner T., Penchaszadeh G.K., Daniels R.J., et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature 1990, 345:823-825.
5. Melki J., Abdelhak S., Sheth P., Bachelot M.F., Burlet P., Marcadet A., et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 1990, 344:767-768.
6. Lefebvre S., Bürglen L., Reboullet S., Clermont O., Burlet P., Viollet L., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
7. Lefebvre S., Burlet P., Liu Q., Bertrandy S., Clermont O., Munnich A., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997, 16:265-269.
8. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000, 15:228-237.
9. Bussaglia E., Clermont O., Tizzano E., Lefebvre S., Bürglen L., Cruaud C., et al. A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat Genet 1995, 11:335-337.
10. Rochette C.F., Surh L.C., Ray P.N., McAndrew P.E., Prior T.W., Burghes A.H.M., et al. Molecular diagnosis of non-deletion SMA patients using quantitative PCR of SMN exon 7. Neurogenetics 1997, 1:141-147.
11. Parsons D.W., McAndrew P.E., Iannaccone S.T., Mendell J.R., Burghes A.H.M., Prior T.W. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet 1998, 63:1712-1723.
12. Harada Y., Sutomo R., Sadewa A.H., Akutsu T., Takeshima Y., Wada H., et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J Neurol 2002, 249:1211-1219.
13. -/- mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000, 9:333-339.
14. Monani U.R., Lorson C.L., Parsons D.W., Prior T.W., Androphy E.J., Burghes A.H.M., et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999, 8:1177-1183.
15. Lorson C.L., Hahnen E., Androphy E.J., Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999, 96:6307-6311.
16. Cartegni L., Krainer A.R. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003, 10:120-125.
17. Cartegni L., Krainer A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002, 30:377-384.
18. Lorson C.L., Androphy E.J. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000, 9:259-265.
19. Kashima T., Manley J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 2003, 34:460-463.
20. Andreassi C., Jarecki J., Zhou J., Coovert D.D., Monani U.R., Chen X., et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001, 10:2841-2849.
21. Zhang M.L., Lorson C.L., Androphy E.J., Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 2001, 8:1532-1538.
22. Grzeschik S.M., Ganta M., Prior T.W., Heavlin W.D., Wang C.H. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005, 58:194-202.
23. Kinali M., Mercuri E., Main M., De Biasia F., Karatza A., Higgins R., et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002, 59:609-610.
24. Angelozzi C., Borgo F., Tiziano F.D., Martella A., Neri G., Brahe C. Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 2008, 45:29-31.
25. Pane M., Staccioli S., Messina S., D'Amico A., Pelliccioni M., Mazzone E.S., et al. Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 2008, 18:536-540.
26. Skordis L.A., Dunckley M.G., Yue B., Eperon I.C., Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 2003, 100:4114-4119.
27. Hua Y., Sahashi K., Hung G., Rigo F., Passini M.A., Bennett C.F., et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010, 24:1634-1644.
28. Williams J.H., Schray R.C., Patterson C.A., Ayitey S.O., Tallent M.K., Lutz G.J. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci 2009, 29:7633-7638.
29. Hua Y., Vickers T.A., Okunola H.L., Bennett C.F., Krainer A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008, 82:834-848.
30. Hastings M.L., Berniac J., Liu Y.H., Abato P., Jodelka F.M., Barthel L., et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med 2009, 1. 5ra12.
31. Baron-Delage S., Abadie A., Echaniz-Laguna A., Melki J., Beretta L. Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 2000, 6:957-968.
32. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001, 98:9808-9813.
33. Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F.A., Raschke H., Blumcke I., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003, 12:2481-2489.
34. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003, 54:647-654.
35. Brahe C., Vitali T., Tiziano F.D., Angelozzi C., Pinto A.M., Borgo F., et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005, 13:256-259.
36. Riessland M., Brichta L., Hahnen E., Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 2006, 120:101-110.
37. Hahnen E., Eyüpoglu I.Y., Brichta L., Haastert K., Tränkle C., Siebzehnrübl F.A., et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006, 98:193-202.
38. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007, 117:659-671.
39. Garbes L., Riessland M., Hölker I., Heller R., Hauke J., Tränkle C., et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 2009, 18:3645-3658.
40. Brichta L., Holker I., Haug K., Klockgether T., Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006, 59:970-975.
41. Tsai L.K., Yang C.C., Hwu W.L., Li H. Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol 2007, 14:e8-9.
42. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
43. Burnett B.G., Muñoz E., Tandon A., Kwon D.Y., Sumner C.J., Fischbeck K.H. Regulation of SMN protein stability. Mol Cell Biol 2009, 29:1107-1115.
44. Göttlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
45. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
46. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004, 12:59-65.
47. Wieser H.G. Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res 1991, 9:154-159.
48. Hofmann Y., Lorson C.L., Stamm S., Androphy E.J., Wirth B. Htra2-β1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000, 97:9618-9623.
49. Hofmann Y., Wirth B. HnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-β1. Hum Mol Genet 2002, 11:2037-2049.
50. Chen W.Y., Weng J.H., Huang C.C., Chung B.C. Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1). Mol Cell Biol 2007, 27:7284-7290.
51. Hutchison S., LeBel C., Blanchette M., Chabot B. Distinct sets of adjacent heterogeneous nuclear ribonucleoprotein (hnRNP) A1/A2 binding sites control 5' splice site selection in the hnRNP A1 mRNA precursor. J Biol Chem 2002, 277:29745-29752.
52. Weihl C.C., Connolly A.M., Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006, 67:500-501.
53. Kelln B.M., McKeon P.O., Gontkof L.M., Hertel J. Hand-held dynamometry: reliability of lower extremity muscle testing in healthy, physically active, young adults. J Sport Rehabil 2008, 17:160-170.
54. Swoboda K.J., Scott C.B., Reyna S.P., Prior T.W., LaSalle B., Sorenson S.L., et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009, 4:e5268.
55. Rak K., Lechner B.D., Schneider C., Drexl H., Sendtner M., Jablonka S. Valproic acid blocks excitability in SMA type I mouse motor neurons. Neurobiol Dis 2009, 36:477-487.
56. Van den Berg R.J., Kok P., Voskuyl R.A. Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res 1993, 93:279-287.
57. Swoboda K.J., Scott C.B., Crawford T.O., Simard L.R., Reyna S.P., Krosschell K.J., et al. S.M.A.C.A.R.N.I.-V.A.L. trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 2010, 5:e12140.
58. Johannessen C.U., Johannessen S.I. Valproate: past, present and future. CNS Drug Reviews 2003, 9:199-216.